Provide Article and Formatting Choices to Summarize Madrigal Pharmaceuticals

I can’t summarise because you didn’t paste the article text or a link. Please either paste the article you want summarised (or a link to it), or tell me you want me to use public news up to my knowledge cutoff (2024‑06) instead.

Before you send the article, please confirm two formatting choices:

- Do you want exactly 300 words in one paragraph, or the requested 300–500 words split into sections (one Main Topic section of three paragraphs and two short paragraphs of other content)?

- Any particular emphasis (e.g., regulatory updates, clinical trial data, partnerships, pipeline developments) other than avoiding stock/price/investment discussion?

When you provide the article (or confirm I may use my public-knowledge option), I will produce a Reuters-style summary specific to Madrigal Pharmaceuticals, present tense, focused on a single development, with:

- A unique Introduction and Topic Header (not generic boilerplate)

- One Main Topic section (three paragraphs) on the single most relevant Madrigal-related development

- Two short paragraphs with other relevant content

- Total length 300–500 words (or exactly 300 words if you choose that option)

Send the article text or link and your choice on the word-length option and emphasis, and I’ll produce the summary.